CINGW
Cingulate Inc. WarrantsNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-1.73
Beta
-0.92
52W High
$0.17
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cingulate Inc. Warrants
Cingulate Inc. Warrants represent a significant investment opportunity associated with a biopharmaceutical firm dedicated to innovating therapies for Attention Deficit Hyperactivity Disorder (ADHD) and related disorders. The company is advancing its lead product, which aims to enhance treatment efficacy and patient tolerability, addressing unmet needs in a growing market. With a solid development pipeline and strategic initiatives for growth, Cingulate Inc. is well-positioned for investors seeking to capitalize on advancements in the healthcare sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.74M |
| EBITDA | $-23.66M |
| Operating Margin | 0.00% |
| Return on Equity | -225.10% |
| Return on Assets | -69.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.58 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $12.94M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Data last updated: 7/9/2026